BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 13, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Regulatory actions for Feb. 4, 2021

Feb. 4, 2021
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: B-Secur, Claronav Kolahi, RapidAI, Precision Biomonitoring, Precision Spine.
Read More

Other news to note for Feb. 4, 2021

Feb. 4, 2021
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: 23andme, Ambu, Coopercompanies, Curadel Surgical Innovations, Bioaffinity Technologies, Dxs, Emitbio, Essilorluxottica, Horizon Therapeutics, Illumina, Insightec, Medidata, Mnx Global Logistics, Mprobe, Neogenomics, Newronika, Oxford Immunotec, Parexel, Philips, Phillips-Medisize, Pieriandx, Quidel, RNA Disease Diagnostics, Sera Prognostics, Shanghai Fosun Long March Medical Science, Sightglass Vision, Stella Diagnostics, Subcuject, Tcg Lifesciences, Varian, Vuzix, Webops.
Read More

BioWorld MedTech’s Diagnostics Extra for Feb. 4, 2021

Feb. 4, 2021
By Meg Bryant
Keeping you up to date on recent developments in diagnostics, including: A deep learning tool to predict cardiovascular risk; Smartphone-based COVID-19 test; PCOS passed on in the epigenes.
Read More
Syringe, bottles of COVID-19 vaccine on U.K. map

U.K. launches mixed COVID-19 vaccine trial

Feb. 4, 2021
By Nuala Moran
LONDON – The U.K has started the world’s first trial alternating an adenoviral vectored COVID-19 vaccine with one that delivers the virus spike protein instructions encoded in messenger RNA. The heterologous prime boost trial will recruit 820 participants into an eight-arm study comparing different combinations of the Astrazeneca plc/Oxford University and Pfizer Inc./Biontech SE vaccines, administered in a different order and at different intervals.
Read More

Regulatory actions for Feb. 4, 2021

Feb. 4, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astellas, Astrazeneca, EMD, Intrommune, Karyopharm, Sinovac, Theratechnologies.
Read More

Other news to note for Feb. 4, 2021

Feb. 4, 2021
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Active, Angelini, Angiotensin, Arvelle, Astrazeneca, Beximco, BMS, BNC, Connectyx, Diamond, Evotec, Famar, Gensight, Golden, Molecular Partners, Neogenomics, Novartis, Novavax, Serum Institute, Sio, Sunshine, Wuxi.
Read More

In the clinic for Feb. 4, 2021

Feb. 4, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: ADC, Agenus, Aldeyra, Aligos, Atea, Biogen, Botanix, Calliditas, Codiak, Corvus, Crinetics, Curevac, Dynavax, Eucure, Gilead, Golden, I-Mab, Innocare, Neurorx, Reistone, Surface Ophthalmology.
Read More
Regulatory front

Industry: Stop Trump’s Part D changes

Feb. 4, 2021
By Mari Serebrov
The latest global regulatory news, changes and updates affecting biopharma, including: FDA weighing Xeljanz safety results; EMA initiates OPEN collaboration; NICE evaluating guidance processes; TGA seeking comments; USPTO extends program with Japan’s, Korea’s patent offices; NICE recommends Keytruda in NSCLC; Florida researcher indicted.
Read More
Digital illustration of U.S., coronavirus

Stenzel says FDA making nine EUA decisions per day vs. one at outset of pandemic

Feb. 3, 2021
By Mark McCarty
The U.S. FDA is still struggling to keep up with the volume of diagnostic emergency use authorizations (EUAs), but it is not for want of effort. Tim Stenzel, director of the FDA’s Office of In Vitro Diagnostics and Radiological Health (OIR), said on the Feb. 3 testing town hall that the agency is processing nine such applications per day, a big jump over the rate of one per day in the early weeks of the COVID-19 pandemic.
Read More
Coronavirus variants

Seegene develops COVID-19 test kit capable of detecting multiple variants

Feb. 3, 2021
By Gina Lee
HONG KONG – Seegene Inc. has developed a COVID-19 test kit that is able to both detect and identify multiple mutant variations of the virus. “Getting test results from the Allplex SARS-CoV-2 Variants Ⅰ Assay takes two hours, which is normally how long getting results from a PCR test takes,” a Seegene spokesperson told BioWorld.
Read More
Previous 1 2 … 289 290 291 292 293 294 295 296 297 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 12, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 9, 2026
  • 3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

    Skape Bio unlocks GPCR targets with de novo-designed miniproteins

    BioWorld
    Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
  • Blood sample tubes after centrifuge

    Pre-disease plasma signature may help redefine lung cancer risk

    BioWorld
    Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
  • New 5-HT2C receptor agonists reported in Hansoh patent

    BioWorld Science
    Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing